Zolistra 4mg Injection

Zolistra 4mg contains the active ingredient Zoledronic Acid, which belongs to the class of medicines known as bisphosphonates. It is used to lower high blood calcium levels (hypercalcaemia) in adults when caused by certain tumours. Some cancers accelerate the normal breakdown of bone tissue, leading to excessive calcium being released into the bloodstream. This condition is called tumour-induced hypercalcaemia (TIH). Zolistra 4mg is also prescribed to prevent bone-related complications in adults with multiple myeloma and bone metastases from solid tumours when used in combination with standard cancer therapy.

In addition, Zolistra 4mg is indicated for the prevention and treatment of osteoporosis in postmenopausal women and in men with decreased bone density. It is also used to treat Paget's disease of bone, a condition in which the bones become enlarged, weak, painful, or more susceptible to fractures. This medicine may also be prescribed to prevent or manage glucocorticoid-induced osteoporosis in men and women receiving long-term corticosteroid therapy, which can weaken bones and increase the risk of fractures.

Do not use Zolistra 4mg if you are allergic to Zoledronic Acid, any other bisphosphonate, or any of the ingredients in this medicine. It should also be avoided during pregnancy and breastfeeding. Before starting treatment, inform your doctor if you have kidney or liver disease, bone disorders, or symptoms such as jaw pain, swelling, or numbness, as these conditions may require careful monitoring throughout therapy. This medicine is not recommended for use in children and adolescents below 18 years of age.

It is important to note that Zolistra 4mg is not a chemotherapy medicine and does not stop or slow the spread of cancer. Instead, it is used to manage bone diseases and skeletal complications in patients with cancer, helping to maintain bone strength and reduce the risk of fractures and other bone-related complications.

Treat hypercalcemia of malignancy Multiple myeloma Bone metastases from solid tumors Osteoporosis in postmenopausal women Osteoporosis in men Paget’s disease of bone

Zolistra 4mg primarily inhibits bone resorption. It works by slowing bone breakdown, increasing bone density (thickness), and decreasing the amount of calcium released from the bones into the blood.

It should only be administered by a trained doctor or nurse. It will be given as a drip (infusion) into your vein. Your doctor will decide the dose and duration of the treatment based on your disease severity and other factors. Do not self-administer the medication.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Nausea, vomiting Fatigue Anemia Bone pain Constipation, diarrhea dyspnea, and fever Swelling in the legs and feet Decreased weight Abdominal pain Muscle pain Tiredness Serious Changes in heart rhythm Severe hypersensitivity skin reactions Decreased calcium levels Severe bone pain Severe kidney problems Unusual fractures of the bone

While being treated with zoledronic you should maintain good oral hygiene and receive routine dental check-ups. Contact your doctor or dentist immediately if you experience any problems with your mouth or teeth, such as loose teeth, pain or swelling, non-healing sores, or discharge. Inform your physician if you have kidney problems. Your doctor may advise you to take certain blood tests regularly to check the effectiveness of the therapy.